CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
2024

CD2AP Deficiency and Alzheimer's Disease

Sample size: 134 publication 10 minutes Evidence: high

Author Information

Author(s): Xue Yan-Yan, Zhang Zhe-Sheng, Lin Rong-Rong, Huang Hui-Fen, Zhu Ke-Qing, Chen Dian-Fu, Tao Qing-Qing, Wu Zhi-Ying

Primary Institution: Zhejiang University School of Medicine

Hypothesis

Does CD2AP deficiency exacerbate Alzheimer's disease phenotypes and pathology through p38 MAPK activation?

Conclusion

CD2AP deficiency worsens Alzheimer's disease symptoms and pathology by activating the p38 MAPK pathway.

Supporting Evidence

  • CD2AP is widely expressed in the mouse brain, particularly in neurons.
  • Neuronal knockout of Cd2ap significantly aggravated tau pathology and cognitive deficits.
  • Knockout of Cd2ap activated p38 MAPK signaling, leading to increased tau phosphorylation.
  • Phenotypes of neuronal Cd2ap knockout were improved by a p38 MAPK inhibitor.

Takeaway

When a protein called CD2AP is missing, it makes Alzheimer's disease worse in mice, affecting their memory and brain health.

Methodology

The study used APP/PS1 mouse models with neuron-specific Cd2ap deletion and CD2AP-knockdown SH-SY5Y cell lines to investigate the effects on Alzheimer's disease pathology.

Potential Biases

Potential bias in behavioral tests due to the lack of blinding in some assessments.

Limitations

The study primarily focused on young mice, and the effects of CD2AP deficiency in older mice were not evaluated.

Participant Demographics

Mice used in the study were primarily C57BL/6J background.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s40035-024-00454-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication